Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 plus glucocorticoids as first-line therapy for primary immune thrombocytopenia
ChiCTR2500105480Phase 2Not yet recruiting
- Sponsor
- Subei People's Hospital
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in immune thrombocytopenia (ITP), sponsored by Subei People's Hospital. Primary endpoint: Platelet response at 8 weeks. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2500105480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105480.